OMICS International announces the International Conference on Hypertension & Treatment to be held during August 04-06, 2016 at Toronto, Canada, focusing on "Hypertension and Treatment" with a view to attract world-class personalities working on Hypertension to provide an opportunity to share knowledge, expertise along with unparalleled networking opportunities between a large number of medical professionals like Directors, Heads, Deans, Professors, Scientists, Researchers, Cardiologists and Writers of the Hypertension or Cardiology and related departments, Founders and Employees of the related companies, Associations, Organizations, Laboratory members and Young researchers working in the field of hypertension treatment and management.
Hypertension-2016 is an international platform for presenting research about Hypertension and related concepts, sharing alternative ideas about the severe cardiovascular risk factor, thus contributing to the dissemination of information about the trouble for the welfare of the society. Hypertension is a major risk factor for cardiovascular diseases, cerebrovascular events and ischemic heart diseases, so is therefore one of the most important preventable causes of premature morbidity and mortality in developed and developing countries. It is often symptomless, so screening is vital before damage is done. Many surveys continue to show that hypertension remains underdiagnosed, undertreated and poorly controlled. Blood Pressure has a skewed normal distribution within the population and the currently accepted model assumes risk is continuously related to BP. Essential hypertension (primary, cause unknown) accounts for the majority of cases, particularly in the older patient.
The prevalence of hypertension is forecasted to grow from 234 million in 2010 to 246 million in 2016 across the seven major markets (France, Germany, Italy, Spain, UK, US, and Japan). In 2016, the US is still expected to be the largest market for hypertension, with an anticipated 83 million sufferers, followed by Japan at 49 million. According to the International Society of Hypertension, there is a clear recognition of hypertension as a major public health issue across all the 7MM.The global cardiovascular market recorded a sale of $170bn in the year 2010 and is set to grow to $187bn in 2016 at a CAGR of 1.6%. The US continued to be the largest market, with a share of 40% of the overall market. Anti-hypertensives remained the largest drug class in the year 2010, with a global sale of $37.6bn and a global market share of 22%.
Keeping the emerging market trends in mind, Canada has been selected as Venue for the International Conference on Hypertension and Treatment. 17.7% (5.3 million) of Canadians aged 12 and older reported being diagnosed with high blood pressure in 2013. This was not a significant change from 2012, though it is an increase from 16.9% in 2009.In 2007/08, about 6 million adults (23.0%) were living with diagnosed hypertension and about 418 000 had a new diagnosis. The age-standardized prevalence increased significantly from 12.5% in 1998/99 to 19.6% in 2007/08, and the incidence decreased from 2.7 to 2.4 per 100.All-cause mortality was higher among adults with diagnosed hypertension than among those without hypertension. These findings highlight the need to continue monitoring the effectiveness of efforts for managing hypertension and to enhance public health programs aimed at preventing hypertension in Canada.
The three days event is expected to implant firm strategies in the field of Hypertension & Treatment. The conceptual and applicable knowledge shared will also foster organizational collaborations to nurture scientific accelerations. We bring together World-eminent speakers, most recent researches, latest treatment techniques and the advanced updates in Hypertension Treatment and Management to highlight the principal features of this conference.